In The News

The high blood pressure drugs Benicar®, Benicar HCT®, Azor® and Tribenazor® have been linked to chronic diarrhea and kidney failure.

Drugmakers Agree to $300M Settlement in MDL Over Hypertension Medication Benicar

Drugmakers Daiichi Sankyo and Forest Laboratories have agreed to a $300 million settlement of multidistrict litigation by users of hypertension drug Benicar who linked their cases of severe diarrhea to use of the drug.

Attorneys placed the settlement on the record before U.S. District Judge Robert Kugler in Camden on Tuesday. The agreement would apply to about 2,000 cases from across the nation that were consolidated before Kugler, as well as another 100 cases pending in state Superior Court in Atlantic County.

READ MORE at New Jersey Law Journal

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar

NEW YORK (Reuters) - Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of failing to warn that its blood pressure medication Benicar can cause gastrointestinal illness.

The settlement will become finalized if at least 95 percent of all claimants agree, or opt in, Daiichi Sankyo said in a statement. The company said the settlement fund was capped at $300 million.

READ MORE at Reuters

Daiichi's Benicar Pact Brings Payout Over Drugs to $339 Million

Daiichi Sankyo Inc.’s settlement of thousands of lawsuits blaming the company’s blood-pressure drugs for causing intestinal damage brings to $339 million the amount the drugmaker has paid for its handling of the medicines.

Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its Benicar, Benicar HCT, Azor and Tribenzor blood-pressure treatments. The accord comes more than two years after the Chuo-Ku, Japan-based company paid $39 million to resolve the U.S. government’s allegations that it paid illegal kickbacks to doctors who prescribed the medicines.


Benicar Lawsuits Settle for $300 Million

Two years after Benicar lawsuits nationwide were centralized into one federal court in New Jersey, drug-makers Daiichi Sankyo and Forest Laboratories have agreed to pay a $300 million settlement.

The $300 million settlement will resolve about 2,300 lawsuits from people who developed a chronic intestinal illness known as sprue-like enteropathy after taking the blood pressure medication olmesartan in Benicar, Azor, or Tribenzor. The payouts for each plaintiff will depend on how many days they were hospitalized and the extent of their intestinal damage.


Free Consultation

Call now at 800-568-9412 or complete our form for a FREE, no-obligation case evaluation.

Your name:
Your contact information
Best time to reach you:

*By submitting this form, I am granting permission to be contacted via phone, email, text or any other means. I am also confirming that I understand that no attorney-client relationship exists without a specific written retainer agreement between myself and a law firm.